Ilixadencel, a Cell-based Immune Primer, plus Sunitinib Versus Sunitinib Alone in Metastatic Renal Cell Carcinoma: A Randomized Phase 2 Study

BACKGROUND: The prognosis of patients with synchronous metastatic renal cell carcinoma (mRCC) is poor. Whereas single-agent tyrosine kinase inhibition (TKI) is clearly insufficient, the effects can be enhanced by combinations with immune checkpoint inhibitors. Innovative treatment options combining...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindskog, Magnus, Laurell, Anna, Kjellman, Anders, Melichar, Bohuslav, Rey, Pablo Maroto, Zieliński, Henryk, Villacampa, Felipe, Bigot, Pierre, Zoltan, Bajory, Parikh, Omi, Alba, David Vazquez, Jellvert, Åsa, Flaskó, Tibor, Gallardo, Enrique, Caparrós, Maria José Ribal, Purkalne, Gunta, Suenaert, Peter, Karlsson-Parra, Alex, Ljungberg, Börje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Kidney Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142735/
https://www.ncbi.nlm.nih.gov/pubmed/35638086
http://dx.doi.org/10.1016/j.euros.2022.03.012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9142735/
https://www.ncbi.nlm.nih.gov/pubmed/35638086
http://dx.doi.org/10.1016/j.euros.2022.03.012

Ejemplares similares